Request an Appointment

Cancer Answer Line:

M-F 8 a.m. - 4:30 p.m. ET

Expand Content

Cancer Clinical Trials Results

ARRY 16231113-1209 The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum (ARRAY BioPharma Inc.) Fairview, Hillcrest, Main Campus  Gynecologic
CASE 981313-662 Sentinal Lymph Node Mapping for Endometrial Cancer Main Campus  Endometrial, Gynecologic
GOG 0213CC444 A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paciltaxel Alone or in Combination with Bevacizumab followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum- Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer Fairview, Hillcrest, Main Campus Phase 3Gynecologic, Ovarian
GOG 0225IRB 12-869 Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival? Main Campus  Gynecologic, Ovarian, Peritoneal
GOG 0229O13-1497 A randomized phase II study with a phase I lead-in to assess the antitumor efficacy of the MEK inhibitor Trametinib alone or in combination with GSK2141795, an AKT inhibitor in patients with recurrent or persistent endometrial cancer. Fairview, Hillcrest, Main Campus  Gynecologic
GOG 023815-257 A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Fairview, Hillcrest, Main Campus  Gynecologic
GOG 0263CC968 Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy. Fairview, Hillcrest, Main CampusStage 1, Stage 2Phase 3Cervical, Gynecologic
GOG 0264CC906 A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advance Stage and Recurrent Chemo-Naive Sex Cord-Stromal Tumors of the Ovary Fairview, Hillcrest, Main CampusStage 2, Stage 3, Stage 4Phase 2Gynecologic, Ovarian
GOG 0274CC00194 A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone. Main Campus Phase 3Cervical, Gynecologic
GOG 027912-1287 A Phase II Trial Evaluating Cisplatin and Gemcitabine Concurrent with Intensity-Modulated Radiation Therapy (IMRT) for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva Main Campus Phase 2Gynecologic
GOG 9923853 A Phase I Study of Carboplatin/Paclitaxel/CTEP-Supplied Bevacizumab (NSC #704865, IND #7921) and CTEP-Supplied Agent ABT-888 (NSC#737664, IND #77840) in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube or primary peritoneal cancer Hillcrest, Main Campus Phase 1Gynecologic
GOG 992913-558 Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients with Locally Advanced Cervical Cancer Stages IB2/IIA with Positive Para-Aortic Lymph Nodes Only and Stage IIB/IIIB/IVA with Positive Lymph Node Hillcrest, Main Campus Phase 1Gynecologic
GYN 49 15-374 A Multicentre Randomised Phase II Study of AZD1775 plus Chemotherapy Versus Chemotherapy Alone in Patients with Platinum-Resistant TP53-Mutated Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Fairview, Hillcrest, Main Campus Phase 2Gynecologic
JAN 1814 14-711 A Randomized, Open-Label Study Comparing the Combination of YONDELIS, and DOXIL/CAELYX,With DOXIL,/CAELYX, Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. Fairview, Hillcrest, Main Campus  Gynecologic
NRG CC002 15-682 Pre-Operative Assessment and Post-Operative Outcomes of Elderly Women with Gynecologic Cancers Protocol Status. Fairview, Hillcrest, Main Campus  Gynecologic
NRG GY001 15-684 A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women with Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum (NRG) Fairview, Hillcrest, Main Campus Phase 2Gynecologic
NRG GY002 15-763 A Phase II Evaluation of Nivolumab, a Fully Human Antibody against PD - 1, in the Treatment of Persistent or Recurrent Cervical Cancer Fairview, Hillcrest, Main Campus Phase 2Gynecologic

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).


Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2015 Cleveland Clinic. All rights reserved.